Evidence map›Paper›PMID 36263666›Full record

GuidelineClinical and molecular hepatology2022

2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.

Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Clinical and molecular hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 212 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
212citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

212 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Guideline
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Guideline
  9. Guideline
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

152 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea

Funding

National Cancer Center 2112570-2
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth most common cancer among men in South Korea, where the prevalence of chronic hepatitis B infection is high in middle and old age. The current practice guidelines will provide useful and sensible advice for the clinical management of patients with HCC. A total of 49 experts in the fields of hepatology, oncology, surgery, radiology, and radiation oncology from the Korean Liver Cancer Association-National Cancer Center Korea Practice Guideline Revision Committee revised the 2018 Korean guidelines and developed new recommendations that integrate the most up-to-date research findings and expert opinions. These guidelines provide useful information and direction for all clinicians, trainees, and researchers in the diagnosis and treatment of HCC.

Indexed as

Carcinoma, HepatocellularHepatitis B, ChronicLiver NeoplasmsHumansMalePrevalenceRepublic of KoreaDiagnosisGuidelinesHepatocellular carcinomaManagement

Identifiers

PMID36263666
PMCPMC9597235

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.